Cohort | PK Parameter | SAconjugates | SBconjugates | ||
---|---|---|---|---|---|
HCV | NAFLD | HCV | NAFLD | ||
280 mg | AUC0–48 h (ng · h/ml) | 1327 (860–1925) | 1003 (672–1456) | 4094 (2465–6308) | 3120 (2247–4233) |
Cmax (ng/ml) | 144 (96–205) | 80 (45–125) | 586 (441–762) | 388 (266–544) | |
Tmax (h) | 2 (1.5, 4.0) | 4.0 (2.0, 12.0) | 2.0 (1.5, 4.0) | 3.0 (2.0, 8.0) | |
t1/2 (h) | 5.7 (4.0–7.7) | 6.4 (4.5–9.0) | 4.3 (3.1–5.6) | 4.5 (2.5–7.2) | |
560 mg | AUC0–48 h (ng · h/ml) | 3468 (1747–6024) | 2844 (1493–4779) | 12,760 (6505–22,432) | 7850 (4501–12,664) |
Cmax (ng/ml) | 339 (169–621) | 278 (126–488) | 1691 (1003–2774) | 1125 (805–1570) | |
Tmax (h) | 3.0 (2.0, 4.0) | 4.0 (4.0, 6.2) | 4.0 (1.0, 4.0) | 3.0 (1.5, 6.0) | |
t1/2 (h) | 6.6 (4.5–9.2) | 7.0 (5.0–9.7) | 4.7 (3.7–6.0) | 6.2 (3.3–10.3) |
SA, silymarin A; SB, silymarin B.